摘要
在美国吗,肺癌导致死亡的主要原因,非小细胞肺癌是其最常见的类型。在过去的几十年中,手术和全身治疗非小细胞肺癌取得了巨大进展,但晚期疾病的预后仍然较差。然而,治疗非小细胞肺癌新的研究是探索使用靶向治疗。间变性淋巴瘤激酶(ALK)参与正常哺乳动物中枢神经系统发育。一种涉及ALK的融合基因以及棘皮动物微管相关蛋白4(EML4)基因与5%的NSCLCs有关,并与其他致癌基因相互排斥。抗ALK靶向治疗重排是一种相对较新的治疗方式,其旨在改善晚期癌症患者的预后。两类药物Crizotinib 和 Ceritinib已经得到了FDA的批准。以及许多其他ALK抑制剂目前正处于临床试验研究阶段。本文对ALK抑制剂治疗NSCLCs进行了总结,并对将来的研究方向和挑战提出了看法。
关键词: 间变性,抑制剂,蛋白激酶,淋巴瘤,非小细胞肺癌(NSCLC)
图形摘要
Current Drug Targets
Title:Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Volume: 17 Issue: 6
Author(s): David M. Straughan, Sad C. Azoury and Vivek Shukla
Affiliation:
关键词: 间变性,抑制剂,蛋白激酶,淋巴瘤,非小细胞肺癌(NSCLC)
摘要: Lung cancer is the leading cause of cancer death among both sexes in the United States and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Over the last several decades, there have been many advances in both surgical approaches and systemic therapies for the treatment of NSCLC, but the prognosis for advanced disease remains poor. New research, however, is exploring the use of targeted therapies for the treatment of NSCLC. The anaplastic lymphoma kinase (ALK) is involved in normal mammalian central nervous system development. A novel fusion gene involving ALK and the echinoderm microtubule-associated protein-like 4 (EML4) gene has been associated with approximately 5% of NSCLCs and is mutually exclusive of other oncogenic driver mutations. Targeted therapies against this ALK rearrangement are a relatively new treatment modality that aims to improve the prognosis of patients with late-stage disease. Two such drugs have Food and Drug Administration (FDA) approval currently: Crizotinib and Ceritinib. Many other ALK inhibitors are currently being studied in clinical trials as well. The authors aim to provide a comprehensive review of ALK inhibitors for use in NSCLC as well as the future directions and challenges to developing these targeted therapies.
Export Options
About this article
Cite this article as:
David M. Straughan, Sad C. Azoury and Vivek Shukla , Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer, Current Drug Targets 2016; 17 (6) . https://dx.doi.org/10.2174/1573399811666150615144336
DOI https://dx.doi.org/10.2174/1573399811666150615144336 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Targets in Malignant Pleural Mesothelioma Treatment
Current Drug Targets Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine The Effect of Protein Restriction in the In Vitro Metabolism of Albendazole in Rats
Drug Metabolism Letters Molecular Pathophysiology of Cavernous Nerve Injury and Identification of Strategies for Nerve Function Recovery After Radical Prostatectomy
Current Drug Targets Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Expanding the Biotherapeutics Realm via miR-34a: “Potent Clever Little” Agent in Breast Cancer Therapy
Current Pharmaceutical Biotechnology Tetralone Scaffolds and Their Potential Therapeutic Applications
Letters in Drug Design & Discovery Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy
Current Pharmaceutical Design Role of Generation, Architecture, pH and Ionic Strength on Successful siRNA Delivery and Transfection by Hybrid PPV-PAMAM Dendrimers
Current Medicinal Chemistry A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Relationships Between Alcohol Consumption, Smoking Status and Food Habits in Greek Adolescents. Vascular Implications for the Future
Current Vascular Pharmacology The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Biologic Therapy in Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Polyphenols: A Diverse Class of Multi-Target Anti-HIV-1 Agents
Current Drug Metabolism Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Current Medicinal Chemistry SPECT-CT in Radiotherapy Planning, with Main Reference to Patients with Breast Cancer
Current Radiopharmaceuticals Targeting CD147 is a Novel Strategy for Antitumor Therapy
Current Pharmaceutical Design S-Phase Kinase-Associated Protein-2 and Nuclear Factor-kappa Beta as Molecular Targets of Oral Burkitt’s Lymphoma Cell Induced by Quinolinone Derivate-Vesnarinone
Current Signal Transduction Therapy